Support Psychedelic Science to Help Change Lives

MAPS is a leader in psychedelic research. Since 1986, MAPS is on a mission to create safe and legal opportunities for the uses of psychedelics in society.

Choose an amount to give

GIVE ONCE MONTHLY

$

USD/mo

Your donation qualifies you to receive the MAPS Bulletin by mail.

Receive a printed copy of the MAPS Bulletin

Together, we can cross the finish line and make MDMA a medicine

The results from the first of two MAPS-sponsored Phase 3 clinical trials for MDMA-assisted therapy for PTSD were statistically significant. The full results have been published. Phase 3 is the final stage before seeking FDA approval for a new prescription treatment.

If successful, this treatment could transform the lives of millions of people who live with the impacts of complex trauma.

Nature Medicine Journal Publication: MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

We’re in the midst of a global renaissance of psychedelic research

"Psychedelics, when used wisely, have the potential to heal us, help inspire us, and perhaps even save us."

—Rick Doblin, Ph.D., MAPS Founder and Executive Director

Watch MAPS Founder Rick Doblin, Ph.D. present the first TED Talk on psychedelics to an audience in Vancouver, British Columbia.

Help us usher in a new paradigm of mental health

“The work we’re doing at MAPS PBC is related to making MDMA-assisted therapy available as a prescription treatment and the mission of MAPS is to do this with total transparency, open science, and putting public benefit first.”

—Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC)

In the May 4, 2021, edition of The New York Times newspaper, the world-renowned publication reveals research results from the first Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD).

Become a Psychedelic Advocate

Monthly MAPS donors sustain our work and support year-round psychedelic research, drug policy reform, public education, harm reduction, peer support, and general operations.

Press Releases

MAPS Achieves Highly Significant Result in Successful Phase 3 Trial of MDMA-Assisted Therapy for PTSD in Patients with Severe, Chronic PTSD

May 3, 2021

First Controlled Trial of Cannabis for the Treatment of PTSD Raises No Safety Concerns, Further Research is Needed to Determine Efficacy

March 17, 2021

Lawsuit Filed Against the DEA and Attorney General to Compel Issuance of Licenses to Manufacture Marijuana for Clinical Trials and Potential FDA Approval

December 3, 2020

MAPS News

Our 35th Anniversary, New Logo, and New Video

Now Hiring - Explore Career Opportunities

MAPS Newsletter: April 2021

The MAPS Bulletin: Winter 2021 is now available online!

Featured Media

The New York Times:
A Psychedelic Drug Passes Big Test for PTSD Treatment

The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

The Washington Post:
Who Will Benefit From Psychedelic Medicine?

Boston Magazine:
The Interview: MDMA-Therapy Expert Dr. Rick Doblin

MDMA-assisted therapy is the only treatment for PTSD designated by the FDA as a breakthrough therapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist therapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored clinical trials of MDMA-assisted therapy for anxiety associated with life-threatening illness and social anxiety in autistic adults, LSD-assisted therapy for anxiety, and medical marijuana for PTSD in veterans of war. We have sponsored observational studies for ibogaine therapy for drug addiction and ayahuasca-assisted treatment for drug addiction and PTSD.

Our Education Programs

In addition to our clinical research programs, MAPS provides harm reduction training and services through the Zendo Project, advocates for reducing barriers to scientific research with psychedelics and marijuana, and curates educational events and webinars.

Our Values

Transparency

Information is shared openly and clearly. Communications are respectful, honest, and forthright.

Passion and Perseverance

We persist in the face of challenges. We have a sense of urgency about our work, and know that it's a long-term effort.

Intelligent Risk

Our decisions are informed by research. We try new things and learn from our mistakes.

Trust and Accountability

We value integrity and honesty, and embrace high standards.

MAPS

We are a 501(c)(3) non-profit research and educational organization developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Watch videos from Psychedelic Science 2017.

Media

About Us

Contact Us

3141 Stevens Creek Blvd #40563
San Jose, CA 95117
Phone: 831-429-MDMA (6362)
Fax: 831-429-6370
Ask MAPS
Media Requests

Log in to your account